Use of Teriparatide to Accelerate Fracture Healing

Stopped early · Not applicable · Has a placebo group

Conditions studied: Pelvic Fracture

In brief

The purpose of this study is to compare the effect of the drug teriparatide to the effect of placebo on pelvic fracture healing.

Key facts

Study ID

NCT00594906

Run by

University of Rochester

People needed

10

Starts

2008-01-01

Expected to finish

2012-07-01

Last updated by the study team

2014-12-19

Who can join

Age: 55 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Females must be menopausal (no menses within the last 12 months)
• Low energy fragility fractures of the pelvis, including anterior column, posterior column, inferior or superior rami, or sacrum
• Maximum of 2 weeks post fracture
• Mental status consistent with completing the study protocol

You may not qualify if…

• Currently receiving any treatment for osteoporosis, including estrogen and estrogenic-like compounds
• Received radiation treatment to any site at any time in the past
• Received chemotherapy for cancer at any time in the past
• Any active cancer
• Surgical repair (or attempted repair) of the fracture site in the pelvis
• Use of any bone-active medications
• Use of anticonvulsant therapy
• Use of immunosuppressants
• Any renal, gastrointestinal, liver, or metabolic bone disease
• Pregnancy
• High calcium, parathyroid hormone, or alkaline phosphatase, as based on laboratory results

Where it is running

• University of Rochester — Rochester, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.